Researchers identify bone-forming cells as the driver of scoliosis caused by a genetic disorder, which can be prevented ...

Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for ...

Spinal deformities such as scoliosis and kyphosis are among the most serious complications of neurofibromatosis type 1 (NF1), a genetic disorder that affects about one in 3,000 people.

Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for ...

Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of stock options to purchase 73,000 ...

Pasithea Therapeutics Corp. (NASDAQ: KTTA) ('Pasithea” or the 'Company”), a clinical-stage biotechnology company developing ...

Illumina, Inc. announced today that it will issue results for the fourth quarter and full year 2025 following the close of ...

Researchers at University College London (UCL) have uncovered a key mechanism that helps the body switch off inflammation—a breakthrough that could lead to new treatments for chronic diseases ...

Data from several dozen human volunteers showed that blocking sEH raised epoxy-oxylipin levels and reduced harmful immune ...

Researchers at University College London (UCL) have uncovered a key mechanism that helps the body switch off inflammation – a ...

This review innovatively proposes the use of electrospinning to fabricate electroactive fibrous scaffolds, which mimic the structure of the extracellular matrix while providing electrical activity, ...